Michael Steurer1, Helga Wagner, Günther Gastl. 1. Division of Haematology and Oncology, Innsbruck University Hospital, Innsbruck, Austria. michael.steurer@uibk.ac.at
Abstract
OBJECTIVES: Anaemia is common in patients with haematologic malignancies. In contrast to solid tumours there are only a few studies exploring anaemia in haematologic cancers. The aim of this study was to determine the prevalence of anaemia (haemoglobin [Hb] <12 g/dL) in patients with chronic lymphocytic leukemia (CLL), multiple myeloma (MM), non-Hodgkin's lymphoma (NHL), and Hodgkin's disease (HD) who were scheduled to receive cyclic chemotherapy. Predictive factors for anaemia development and anaemia treatment were also assessed. METHODS: This prospective chart survey was conducted at 35 oncology centers in Austria. A total of 273 patients were followed through four cycles of nonplatinum chemotherapy, and Hb-levels and anaemia therapy were documented. RESULTS: At baseline, prevalence of anaemia was greatest in patients with MM (77.4%). Prevalence of anaemia increased for all malignancies after cycle 4, with the largest increases noted for patients with NHL (from 35.1% at baseline to 73.7%) and HD (from 21.9% to 54.5%). Cyclic chemotherapy and prior anticancer treatment indicated an increased risk for developing anaemia. Notably, 27.5% of patients with Hb levels <10.5 g/dL remained untreated. Transfusions were most often given to patients with severe anaemia (Hb < 8 g/dL), and erythropoietin most often given to patients with mild or moderate anaemia. CONCLUSIONS: Our data confirm that anaemia prevalence in patients with haematologic malignancies is high and increases with chemotherapy. The current practice of anaemia management in these patients leaves room for improvement.
OBJECTIVES:Anaemia is common in patients with haematologic malignancies. In contrast to solid tumours there are only a few studies exploring anaemia in haematologic cancers. The aim of this study was to determine the prevalence of anaemia (haemoglobin [Hb] <12 g/dL) in patients with chronic lymphocytic leukemia (CLL), multiple myeloma (MM), non-Hodgkin's lymphoma (NHL), and Hodgkin's disease (HD) who were scheduled to receive cyclic chemotherapy. Predictive factors for anaemia development and anaemia treatment were also assessed. METHODS: This prospective chart survey was conducted at 35 oncology centers in Austria. A total of 273 patients were followed through four cycles of nonplatinum chemotherapy, and Hb-levels and anaemia therapy were documented. RESULTS: At baseline, prevalence of anaemia was greatest in patients with MM (77.4%). Prevalence of anaemia increased for all malignancies after cycle 4, with the largest increases noted for patients with NHL (from 35.1% at baseline to 73.7%) and HD (from 21.9% to 54.5%). Cyclic chemotherapy and prior anticancer treatment indicated an increased risk for developing anaemia. Notably, 27.5% of patients with Hb levels <10.5 g/dL remained untreated. Transfusions were most often given to patients with severe anaemia (Hb < 8 g/dL), and erythropoietin most often given to patients with mild or moderate anaemia. CONCLUSIONS: Our data confirm that anaemia prevalence in patients with haematologic malignancies is high and increases with chemotherapy. The current practice of anaemia management in these patients leaves room for improvement.
Authors: C Rozman; E Montserrat; J M Rodríguez-Fernández; R Ayats; T Vallespí; R Parody; A Ríos; D Prados; M Morey; F Gomis Journal: Blood Date: 1984-09 Impact factor: 22.113
Authors: J F San Miguel; R García-Sanz; M González; M J Moro; J M Hernández; F Ortega; D Borrego; M Carnero; F Casanova; R Jiménez Journal: Blood Date: 1995-01-15 Impact factor: 22.113
Authors: Heinz Ludwig; Rayko Evstatiev; Gabriela Kornek; Matti Aapro; Thomas Bauernhofer; Veronika Buxhofer-Ausch; Michael Fridrik; Dietmar Geissler; Klaus Geissler; Heinz Gisslinger; Elisabeth Koller; Gerhard Kopetzky; Alois Lang; Holger Rumpold; Michael Steurer; Houman Kamali; Hartmut Link Journal: Wien Klin Wochenschr Date: 2015-09-15 Impact factor: 1.704